uk renal registry 16th annual report figure 13.1. median height z-scores for transplant patients 16...
DESCRIPTION
UK Renal Registry 16th Annual Report Figure Median BMI z-scores for transplant patientsTRANSCRIPT
UK Renal Registry 16th Annual Report
Figure 13.1. Median height z-scores for transplant patients <16 years in 2012
UK Renal Registry 16th Annual Report
Figure 13.2. Median weight z-scores for transplant patients <16 years in 2012
UK Renal Registry 16th Annual Report
Figure 13.3. Median BMI z-scores for transplant patients <16 years in 2012
UK Renal Registry 16th Annual Report
Figure 13.4. Median height z-scores for dialysis patients <16 years in 2012
UK Renal Registry 16th Annual Report
Figure 13.5. Median weight z-scores for dialysis patients <16 years in 2012
UK Renal Registry 16th Annual Report
Figure 13.6. Median BMI z-scores for dialysis patients <16 years in 2012
UK Renal Registry 16th Annual Report
Figure 13.7. BMI categorisation in children <16 yearsby modality in 2012
UK Renal Registry 16th Annual Report
Figure 13.8. Use of growth hormone in children <16 years with a height under 2SD in the UK between 2001 and 2012
UK Renal Registry 16th Annual Report
Figure 13.9. Median systolic blood pressure z-scores for transplant patients <16 years in 2012
UK Renal Registry 16th Annual Report
Figure 13.10. Median systolic blood pressure z-scores for dialysis patients <16 years in 2012
UK Renal Registry 16th Annual Report
Figure 13.11. The percentage of patients <16 years achieving the treatment standard for haemoglobin between 2001–2012, by treatment modality
UK Renal Registry 16th Annual Report
Figure 13.12. The achievement of haemoglobin treatment standardsin paediatric transplant patients <16 years, by the level of graft function
This figures combines all data from 2001–2012.
UK Renal Registry 16th Annual Report
Figure 13.13. The achievement of haemoglobin treatment standards in paediatric transplant patients <16 years, by use of MMF between 2001–2012
UK Renal Registry 16th Annual Report
Figure 13.14. The use of erythropoietin and IV iron in paediatric patients<16 years between 2001 and 2012 by treatment modality